Description
An inhibitor of the receptor tyrosine kinases c-Abl, Bcr-Abl, PDGFR, and c-Kit; inhibits ligand-stimulated autophosphorylation of PDGFR and c-Kit (IC50s = ~0.3 and ~0.1 μM, respectively); inhibits the proliferation of Bcr-Abl-dependent R10(–) cells (IC50s = ~35-40 nM) and HMC-1 cells expressing constitutively active c-Kit in a concentration-dependent manner; prolongs survival in a mouse model of chronic myeloid leukemia at 100 mg/kg twice daily; inhibits replication of MERS-CoV and SARS-CoV in Vero E6 cells at 25 and 50 µM; reduces viral titers in IBV-infected Vero cells at 10 µM
Formal name: 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide, monomethanesulfonate
Synonyms: CGP57148B|STI-571
Molecular weight: 589.7
CAS: 220127-57-1
Purity: ≥98%
Formulation: A crystalline solid
Application||Product Type|Biochemicals|Antivirals|Entry/fusion Inhibitors||Product Type|Biochemicals|Kinase Inhibitors|Abl Family & Bcr-Abl||Product Type|Biochemicals|Kinase Inhibitors|PDGFR Family||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Cell Signaling|Abl family & Bcr-Abl Signaling||Research Area|Cancer|Cell Signaling|Growth Factor Receptor Signaling||Research Area|Immunology & Inflammation|Pulmonary Diseases|MERS||Research Area|Immunology & Inflammation|Pulmonary Diseases|SARS||Research Area|Infectious Disease|Viral Diseases|Coronaviruses